Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-09-11

Clinical Trial Update: Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL [Phase 2]

View source ↗

Summary

A Phase 2 trial is investigating a five-drug combination (tislelizumab, cyclophosphamide, liposomal mitoxantrone, chidamide, and prednisone) for newly diagnosed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CYCLOPHOSPHAMIDE (Cyclophosphamide)
  • Chidamide (chidamide)
  • Mitoxantrone liposomes (liposomal mitoxantrone)
  • PREDNISONE (Prednisone)
  • Tislelizumab (tislelizumab)

Snippet

Sponsor: The Affiliated Hospital of Xuzhou Medical University | Conditions: New Diagnosed Angioimmunoblastic T-Cell Lymphoma | Phase 2 | Status: RECRUITING